Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HVN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM; NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team.

PLoS One. 2018 Sep 20;13(9):e0202753. doi: 10.1371/journal.pone.0202753. eCollection 2018.

2.

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers.

Suksanpaisan L, Xu R, Tesfay MZ, Bomidi C, Hamm S, Vandergaast R, Jenks N, Steele MB, Ota-Setlik A, Akhtar H, Luckay A, Nowak R, Peng KW, Eldridge JH, Clarke DK, Russell SJ, Diaz RM.

Mol Ther Oncolytics. 2018 Jul 5;10:1-13. doi: 10.1016/j.omto.2018.05.001. eCollection 2018 Sep 28.

3.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.

Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW.

J Infect Dis. 2018 Jun 25. doi: 10.1093/infdis/jiy293. [Epub ahead of print]

PMID:
29939296
4.

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.

Sneller MC, Justement JS, Gittens KR, Petrone ME, Clarridge KE, Proschan MA, Kwan R, Shi V, Blazkova J, Refsland EW, Morris DE, Cohen KW, McElrath MJ, Xu R, Egan MA, Eldridge JH, Benko E, Kovacs C, Moir S, Chun TW, Fauci AS.

Sci Transl Med. 2017 Dec 6;9(419). pii: eaan8848. doi: 10.1126/scitranslmed.aan8848.

PMID:
29212716
5.

Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.

Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH.

J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190-17. [Epub ahead of print]

6.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network.

Clin Vaccine Immunol. 2017 Nov 6;24(11). pii: e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov.

7.

Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Nasar F, Matassov D, Seymour RL, Latham T, Gorchakov RV, Nowak RM, Leal G, Hamm S, Eldridge JH, Tesh RB, Clarke DK, Weaver SC.

J Virol. 2017 Mar 29;91(8). pii: e01729-16. doi: 10.1128/JVI.01729-16. Print 2017 Apr 15.

8.

An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model.

Bagley KC, Schwartz JA, Andersen H, Eldridge JH, Xu R, Ota-Setlik A, Geltz JJ, Halford WP, Fouts TR.

Viral Immunol. 2017 Apr;30(3):178-195. doi: 10.1089/vim.2016.0136. Epub 2017 Jan 13.

PMID:
28085634
9.

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.

Mpendo J, Mutua G, Nyombayire J, Ingabire R, Nanvubya A, Anzala O, Karita E, Hayes P, Kopycinski J, Dally L, Hannaman D, Egan MA, Eldridge JH, Syvertsen K, Lehrman J, Rasmussen B, Gilmour J, Cox JH, Fast PE, Schmidt C.

PLoS One. 2015 Aug 7;10(8):e0134287. doi: 10.1371/journal.pone.0134287. eCollection 2015.

10.

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).

Fuchs JD, Frank I, Elizaga ML, Allen M, Frahm N, Kochar N, Li S, Edupuganti S, Kalams SA, Tomaras GD, Sheets R, Pensiero M, Tremblay MA, Higgins TJ, Latham T, Egan MA, Clarke DK, Eldridge JH; HVTN 090 Study Group and the National Institutes of Allergy and Infectious Diseases HIV Vaccine Trials Network, Mulligan M, Rouphael N, Estep S, Rybczyk K, Dunbar D, Buchbinder S, Wagner T, Isbell R, Chinnell V, Bae J, Escamilla G, Tseng J, Fair R, Ramirez S, Broder G, Briesemeister L, Ferrara A.

Open Forum Infect Dis. 2015 Jun 5;2(3):ofv082. doi: 10.1093/ofid/ofv082. eCollection 2015 Sep.

11.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.

12.

Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Mire CE, Matassov D, Geisbert JB, Latham TE, Agans KN, Xu R, Ota-Setlik A, Egan MA, Fenton KA, Clarke DK, Eldridge JH, Geisbert TW.

Nature. 2015 Apr 30;520(7549):688-691. doi: 10.1038/nature14428. Epub 2015 Apr 8.

13.

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, Zagursky RJ, Egan MA, Eldridge JH, LaBranche CC, Montefiori DC, Le Buanec H, Zagury D, Pal R, Pavlakis GN, Felber BK, Franchini G, Gordon S, Vaccari M, Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13. Erratum in: Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2413.

14.

Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Xu R, Nasar F, Megati S, Luckay A, Lee M, Udem SA, Eldridge JH, Egan MA, Emini E, Clarke DK.

J Virol. 2009 Oct;83(19):9813-23. doi: 10.1128/JVI.00550-09. Epub 2009 Jul 22.

15.

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2009 Jan 7;27(2):243-9. doi: 10.1016/j.vaccine.2008.10.051. Epub 2008 Nov 7.

16.

Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines.

Xu R, Megati S, Roopchand V, Luckay A, Masood A, Garcia-Hand D, Rosati M, Weiner DB, Felber BK, Pavlakis GN, Sidhu MK, Eldridge JH, Egan MA.

Vaccine. 2008 Sep 2;26(37):4819-29. doi: 10.1016/j.vaccine.2008.06.103. Epub 2008 Jul 25.

PMID:
18657584
17.

Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.

Megati S, Garcia-Hand D, Cappello S, Roopchand V, Masood A, Xu R, Luckay A, Chong SY, Rosati M, Sackitey S, Weiner DB, Felber BK, Pavlakis GN, Israel ZR, Smith LR, Eldridge JH, Sidhu MK, Egan MA.

Vaccine. 2008 Sep 19;26(40):5083-94. doi: 10.1016/j.vaccine.2008.03.092. Epub 2008 Apr 24.

PMID:
18485543
18.

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.

Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC.

Clin Vaccine Immunol. 2008 Jul;15(7):1042-53. doi: 10.1128/CVI.00397-07. Epub 2008 Apr 30.

19.

Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids.

Jalah R, Rosati M, Kulkarni V, Patel V, Bergamaschi C, Valentin A, Zhang GM, Sidhu MK, Eldridge JH, Weiner DB, Pavlakis GN, Felber BK.

DNA Cell Biol. 2007 Dec;26(12):827-40.

PMID:
17979522
20.

Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.

Elliott MB, Chen T, Terio NB, Chong SY, Abdullah R, Luckay A, Egan MA, Boutilier LA, Melville K, Lerch RA, Long D, Eldridge JH, Parks CL, Udem SA, Hancock GE.

Vaccine. 2007 Oct 10;25(41):7132-44. Epub 2007 Aug 21.

PMID:
17850933
21.

Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques.

Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, Schadeck EB, Boyer JD, Pavlakis GN, Weiner DB, Sidhu M, Eldridge JH, Israel ZR.

Vaccine. 2007 Jun 21;25(26):4967-82. Epub 2007 Feb 14.

PMID:
17335943
22.

Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.

Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, Rosati M, Felber BK, Pavlakis GN, Mathiesen I, Israel ZR, Eldridge JH, Egan MA.

J Virol. 2007 May;81(10):5257-69. Epub 2007 Feb 28.

23.

Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization.

von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, Franchini G, Albert PS, Bischofberger N, Boyer JD, Weiner DB, Markham P, Israel ZR, Eldridge JH, Pavlakis GN, Felber BK.

J Virol. 2007 Feb;81(4):1972-9. Epub 2006 Nov 29.

24.

Epitope mapping of full-length glycoprotein D from HSV-2 reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junction.

Cooper D, Mester JC, Guo M, Nasar F, Souza V, Dispoto S, Sidhu M, Hagen M, Eldridge JH, Natuk RJ, Pride MW.

Cell Immunol. 2006 Feb;239(2):113-20. Epub 2006 Jun 9.

PMID:
16762332
25.

Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.

Natuk RJ, Cooper D, Guo M, Calderon P, Wright KJ, Nasar F, Witko S, Pawlyk D, Lee M, DeStefano J, Tummolo D, Abramovitz AS, Gangolli S, Kalyan N, Clarke DK, Hendry RM, Eldridge JH, Udem SA, Kowalski J.

J Virol. 2006 May;80(9):4447-57.

26.

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques.

Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A, Garcia-Hand D, Cappello S, Roopchand V, Megati S, Quiroz J, Boyer JD, Felber BK, Pavlakis GN, Weiner DB, Eldridge JH, Israel ZR.

Vaccine. 2006 May 22;24(21):4677-87. Epub 2005 Oct 26.

PMID:
16288822
27.

Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice.

Egan MA, Megati S, Roopchand V, Garcia-Hand D, Luckay A, Chong SY, Rosati M, Sackitey S, Weiner DB, Felber BK, Pavlakis GN, Israel ZR, Eldridge JH, Sidhu MK.

Vaccine. 2006 May 22;24(21):4510-23. Epub 2005 Aug 19.

PMID:
16140439
28.

Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus.

Egan MA, Chong SY, Megati S, Montefiori DC, Rose NF, Boyer JD, Sidhu MK, Quiroz J, Rosati M, Schadeck EB, Pavlakis GN, Weiner DB, Rose JK, Israel ZR, Udem SA, Eldridge JH.

AIDS Res Hum Retroviruses. 2005 Jul;21(7):629-43.

PMID:
16060834
29.

Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.

Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, Schadeck EB, Johnson JE, Masood A, Piacente P, Druilhet RE, Barras PW, Hasselschwert DL, Reilly P, Mishkin EM, Montefiori DC, Lewis MG, Clarke DK, Hendry RM, Marx PA, Eldridge JH, Udem SA, Israel ZR, Rose JK.

AIDS Res Hum Retroviruses. 2004 Sep;20(9):989-1004.

PMID:
15585086
30.

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.

Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, Piacente P, Ma BJ, Montefiori DC, Haynes BF, Israel ZR, Eldridge JH, Staats HF.

Vaccine. 2004 Sep 9;22(27-28):3774-88.

PMID:
15315859
31.
32.

Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A.

Tiberio L, Fletcher L, Eldridge JH, Duncan DD.

Vaccine. 2004 Mar 29;22(11-12):1515-23.

PMID:
15063577
33.

A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.

Periwal SB, Kourie KR, Ramachandaran N, Blakeney SJ, DeBruin S, Zhu D, Zamb TJ, Smith L, Udem S, Eldridge JH, Shroff KE, Reilly PA.

Vaccine. 2003 Jan 17;21(5-6):376-85.

PMID:
12531635
34.

Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

Tebbey PW, Scheuer CA, Peek JA, Zhu D, LaPierre NA, Green BA, Phillips ED, Ibraghimov AR, Eldridge JH, Hancock GE.

Vaccine. 2000 Jun 1;18(24):2723-34.

PMID:
10781860
35.

Combined systemic and mucosal immunization with microsphere-encapsulated inactivated simian immunodeficiency virus elicits serum, vaginal, and tracheal antibody responses in female rhesus macaques.

Israel ZR, Gettie A, Ishizaka ST, Mishkin EM, Staas J, Gilley R, Montefiori D, Marx PA, Eldridge JH.

AIDS Res Hum Retroviruses. 1999 Aug 10;15(12):1121-36.

PMID:
10461832
36.

Induction of mucosal antibody responses by microsphere-encapsulated formalin-inactivated simian immunodeficiency virus in a male urethral challenge model.

Ishizaka ST, Israel ZR, Gettie A, Mishkin EM, Staas JK, Gilley RM, Dailey PJ, Montefiori DC, Marx PA, Eldridge JH.

Vaccine. 1999 Jul 16;17(22):2817-25.

PMID:
10438051
37.

Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.

Greenway TE, Eldridge JH, Ludwig G, Staas JK, Smith JF, Gilley RM, Michalek SM.

Vaccine. 1998 Aug;16(13):1314-23.

PMID:
9682396
38.

Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization.

Wu HY, Nikolova EB, Beagley KW, Eldridge JH, Russell MW.

Infect Immun. 1997 Jan;65(1):227-35.

39.

Host responses induced by co-infection with Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans in a murine model.

Chen PB, Davern LB, Katz J, Eldridge JH, Michalek SM.

Oral Microbiol Immunol. 1996 Aug;11(4):274-81.

PMID:
9002881
40.

Peritoneal cavity CD5 (Bla) B cells: cytokine induced IgA secretion and homing to intestinal lamina propria in SCID mice.

Beagley KW, Murray AM, McGhee JR, Eldridge JH.

Immunol Cell Biol. 1995 Oct;73(5):425-32.

PMID:
8595920
41.

IgA production by peritoneal cavity B cells is IL-6 independent: implications for intestinal IgA responses.

Beagley KW, Bao S, Ramsay AJ, Eldridge JH, Husband AJ.

Eur J Immunol. 1995 Jul;25(7):2123-6.

PMID:
7621888
42.

Generation of monoclonal antibodies to Macaca mulatta (rhesus) IgA.

Ward DC, Jackson S, Eldridge JH, Radl J, Michalek SM.

J Med Primatol. 1995 Feb;24(2):74-80.

PMID:
8613976
43.

Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine.

Greenway TE, Eldridge JH, Ludwig G, Staas JK, Smith JF, Gilley RM, Michalek SM.

Vaccine. 1995;13(15):1411-20.

PMID:
8578818
44.

Do CD5 B cells respond to oral antigens?

Beagley KW, Black CA, DiFabio S, McGhee JR, Kearney JF, Eldridge JH.

Adv Exp Med Biol. 1995;371B:1439-44. No abstract available.

PMID:
7502833
45.

Oral immunization studies with Streptococcus mutans and influenza vaccines in rhesus macaque monkeys.

Michalek SM, Lackner AA, Katz J, Russell MW, Eldridge JH, Mestecky J, Lallone R, Moldoveanu Z.

Adv Exp Med Biol. 1995;371B:1423-9. No abstract available.

PMID:
7502831
46.

Decreased IgA-producing cells in the gut of SIV-infected rhesus monkeys.

Jackson S, Moldoveanu Z, Mestecky J, Pitts AM, Eldridge JH, McGhee JR, Miller CJ, Marx PA.

Adv Exp Med Biol. 1995;371B:1035-8. No abstract available.

PMID:
7502747
47.

Peyer's patch CD8+ memory T cells secrete T helper type 1 and type 2 cytokines and provide help for immunoglobulin secretion.

Lagoo AS, Eldridge JH, Lagoo-Deenadaylan S, Black CA, Ridwan BU, Hardy KJ, McGhee JR, Beagley KW.

Eur J Immunol. 1994 Dec;24(12):3087-92.

PMID:
7805737
48.

Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.

Kozlowski PA, Chen D, Eldridge JH, Jackson S.

AIDS Res Hum Retroviruses. 1994 Jul;10(7):813-22.

PMID:
7986587
49.

Characterization of T and B cells isolated from mucosa-associated tissues of the rhesus macaque.

Kang DW, Ohkawa S, Difabio S, Merrill KW, Fujihashi K, Yamamoto M, Miller CJ, Marthas M, McGhee JR, Eldridge JH, et al.

Cell Immunol. 1993 Oct 15;151(2):379-91.

PMID:
8402944
50.

New advances in vaccine delivery systems.

Eldridge JH, Staas JK, Chen D, Marx PA, Tice TR, Gilley RM.

Semin Hematol. 1993 Oct;30(4 Suppl 4):16-24; discussion 25. Review.

PMID:
8303306

Supplemental Content

Loading ...
Support Center